Nesp 20 mcg/0.5ml pre-filled syringes

Marketed by Dexa Medica

Ingredients in every 0.5 ml

Darbepoetin alfa 20 mcg

Each package contains

1 syringe of 0.5 ml

Other details

Dosage form:Syringe; pre-filled
Flavour: None

W.H.O. classification

ATC Level 1: B - Blood and blood forming organs
ATC Level 2: B03 - Antianemic Preparations
ATC Level 3: B03X - Other Antianemic Preparations in ATC

Warnings

Pregnancy

NOT SAFEThis item is not safe for use during pregnancy.

Lactation

NOT SAFEThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

SAFE IF PRESCRIBEDThis item is safe for use while operating heavy machinery.

Available in

Indonesia

Dosage information

0 TO 18 YEARS OLD
The safety of NESP in babies with low birthweight, neonates, suckling babies, infants or children has not been established.

18 YEARS OLD AND ABOVE
Hemodialysis patients
– Initial dose
The usual dose of Nesp in Adults patients is 20 µg as darbepoetin alfa (genetic recombination), to be administered as a single intravenous injection once weekly.
– Initial dose at the switching from erythropoietin preparations (epoetin alfa (genetic recombination), epoetin beta (genetic recombination), etc).
The usual dose of Nesp in Adults patients is 15-60 µg as darbepoetin alfa (genetic recombination), to be administered as a single intravenous injection once weekly.
– Maintenance dose
When correction of anemia is achieved, the usual dose of Nesp in Adults patients is 15-60 µg as darbepoetin alfa (genetic recombination), to be administered as a single intravenous injection once weekly. If alleviation of anemia is maintained by once weekly injection, the frequency of administration can be changed to once every two weeks with an initial dose set to be two-fold of the dose in the once weekly injection. In this case, the usual dose in Adults patients is 30-120 µg administered as a single intravenous injection once every two weeks.
In all cases, the dose should be adjusted in view of the degree of anemic symptoms and the patient’s age, and should not exceed 180 µg as a single injection.
Initiate treatment when the hemoglobin level is less than 10 g/dl. If the hemoglobin level approaches or exceeds 11 g/dl, reduce or interrupt the dose of darbepoetin alfa (genetic recombinant).

Patients with chronic kidney disease not on dialysis
– Initial dose
The usual dose of Nesp in Adults patients is 30 µg as darbepoetin alfa (genetic recombination), to be administered as a single injection once every two weeks subcutaneously or intravenously.
– Initial dose at the switching from erythropoietin preparations (epoetin alfa (genetic recombination), epoetin beta (genetic recombination), etc).
The usual dose of Nesp in Adults patients is 30-120 µg as darbepoetin alfa (genetic recombination), to be administered as a single injection once every two weeks subcutaneously or intravenously.
– Maintenance dose
When correction of anemia is achieved, the usual dose of Nesp in Adults patients is 30-120 µg as darbepoetin alfa (genetic recombination), to be administered as a single injection once every two weeks subcutaneously or intravenously. If alleviation of anemia is maintained by once every two weeks injection, the frequency of administration can be changed to once every four weeks with an initial dose set to be two-fold of the dose in the once every two weeks injection. In this case, the usual dose in Adults patients is 60-180 µg administered as a single injection once every four weeks subcutaneously or intravenously.
In all cases, the dose should be adjusted in view of the degree of anemic symptoms and the patient’s age, and should not exceed 180 µg as a single injection.
Consider initiating darbepoetin alfa treatment only when the hemoglobin level is less than 10 g/dl and the following consideration apply: (1) the rate of hemoglobin decline indicates the likelihood of requiring a RBC transfusion and (2) reducing the risk of alloimmunization and/or other RBC transfusion-related risks is a goal. If the hemoglobin level exceeds 10 g/dl, reduce or interrupt the dose of darbepoetin alfa, and use the lowest dose of darbepoetin alfa sufficient to reduce the need for RBC transfusions.

OTHER DETAILS
When NESP is used in elderly patients, parameters such as the blood pressure, hemoglobin concentration and hematocrit level should be frequently measured so that the dosage and the frequency of administration can be appropriately adjusted. The elderly generally have reduced physiological function and are likely to have cardiovascular complications such as hypertension.

Indication

Anemia associated with chronic kidney disease (CKD) in patients on hemodialysis or not on dialysis.

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.